One Brave Idea
Through a $75 million investment over at least five years, the American Heart Association and Verily, with support from AstraZeneca, are embarking on a groundbreaking research enterprise focused on preventing or reversing coronary heart disease and, ultimately, improving and restoring cardiovascular health. This marks the start of a bold and new chapter as the largest one-time investment in a team with a focus to end coronary heart disease.
See what people are Saying
"THE BEST IDEA SHOULD TRIUMPH. IT COULD BE A TEENAGER IN WISCONSIN
WHO HAS A BRILLIANT IDEA."
"WE TRUST IN THE POTENTIAL OF IDEAS AND WILL PURSUE THEM, ALONE AND WITH OTHERS, UNTIL WE HAVE TRANSFORMED THE TREATMENT OF DISEASE."- PASCAL SORIOT, CEO, ASTRAZENECA
"WE INTEND TO CHANGE THE WAY
CARDIOVASCULAR RESEARCH IS CONDUCTED."